FACULTY
Achieving Glycemic Control in Type II Diabetes: Where Are We in 2008?
The contents of this issue of University of Tennessee Advanced Studies in Pharmacy include 2 review articles and 2 case studies
Activity Date: November 2008  — Activity Info: Volume 5, (9)
Goals & Objectives | Faculty | Complete Pre-Test Activity | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired)

 

Full Disclosure Policy Affecting CE Activities:
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with a commercial interest. The Course Director and Participating Faculty reported the following:

COURSE DIRECTOR

L. Brian Cross, PharmD, CDE
Associate Professor
University of Tennessee Health Science Center
Colleges of Pharmacy and Medicine
Memphis, Tennessee
Pharmacotherapy Specialist
Holston Medical Group
Department of Disease Management
Kingsport, Tennessee
• Dr Cross reports serving as a consultant for Amylin Pharmaceuticals, Inc, Eli Lilly and Company, and Sanofi-Aventis; and on the speakers' bureau for Amylin Pharmaceuticals, Inc, and Eli Lilly and Company.


PARTICIPATING FACULTY

Vivian A. Fonseca, MD
Professor of Medicine and Pharmacology
Chief of Diabetes Program
Tulane University School of Medicine
New Orleans, Louisiana
• Dr Fonseca reports receiving research support grants (to Tulane) from the American Diabetes Association, AstraZeneca, Daiichi-Sankyo, Inc, Eli Lilly and Company, GlaxoSmithKline, National Institutes of Health, Novartis Pharmaceuticals Corporation, Novo-Nordisk Inc, Pfizer Inc, Sanofi-Aventis, and Takeda Pharmaceuticals North America, Inc; and receiving honoraria for consulting and lectures from Daiichi-Sankyo, Inc, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Novo-Nordisk Inc, Pfizer Inc, Sanofi-Aventis, and Takeda Pharmaceuticals North America, Inc.

Charles D. Ponte, PharmD, BC-ADM, BCPS, CDE, FAPhA, FASHP, FCCP
Professor of Clinical Pharmacy and Family Medicine
West Virginia University School of Medicine
Morganton, West Virginia
• Dr Ponte reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Condit F. Steil, PharmD, CDE
Associate Professor of Pharmacy Practice
Samford University
McWhorter School of Pharmacy
Birmingham, Alabama
• Dr Steil reports serving on the speakers' bureau for Eli Lilly and Company, HDI, Novo-Nordisk Inc, and Pfizer Inc; and serving on the consultant panel for HDI.

Notice: No faculty member has indicated that his article will include information on off-label products.

University of Tennessee Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. University of Tennessee Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

     
Home | Contact Us | View Account | Need Help?